# Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma

> **NCT02630030** · EARLY_PHASE1 · COMPLETED · sponsor: **Emory University** · enrollment: 3 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Ixazomib

## Key facts

- **NCT ID:** NCT02630030
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-24
- **Primary completion:** 2018-07-01
- **Final completion:** 2020-09-03
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2021-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02630030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02630030, "Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02630030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*